0001415889-23-014345.txt : 20231017 0001415889-23-014345.hdr.sgml : 20231017 20231017164352 ACCESSION NUMBER: 0001415889-23-014345 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231016 FILED AS OF DATE: 20231017 DATE AS OF CHANGE: 20231017 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Garland J. Scott CENTRAL INDEX KEY: 0001533228 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39712 FILM NUMBER: 231330034 MAIL ADDRESS: STREET 1: 210 EAST GRAND AVE. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Olema Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001750284 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 300409740 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 780 BRANNAN STREET CITY: SAN FRANCISCO STATE: CA ZIP: 94103 BUSINESS PHONE: (415) 651-3316 MAIL ADDRESS: STREET 1: 780 BRANNAN STREET CITY: SAN FRANCISCO STATE: CA ZIP: 94103 4 1 form4-10172023_081046.xml X0508 4 2023-10-16 0001750284 Olema Pharmaceuticals, Inc. OLMA 0001533228 Garland J. Scott C/O OLEMA PHARMACEUTICALS, INC. 780 BRANNAN ST SAN FRANCISCO CA 94103 true false false false 0 Stock Option (Right to Buy) 10.54 2023-10-16 4 A 0 21520 0 A 2033-10-15 Common Stock 21520 21520 D Stock Option (Right to Buy) 10.54 2023-10-16 4 A 0 14347 0 A 2033-10-15 Common Stock 14347 14347 D The shares subject to the option vest in a series of 36 successive equal monthly installments measured from October 16, 2023, subject to the Reporting Person's continuous service through each applicable vesting date. The shares subject to the option vest in equal monthly installments measured from October 16, 2023, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares will vest in full on the earlier of June 16, 2024 and the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date. /s/ Shane Kovacs, Attorney-in-Fact 2023-10-17